Bioinformatics Senior Scientist
Flomics is a fast-growing biotech company founded in 2018 in Barcelona. We are developing a revolutionary liquid biopsy test for the early detection of cancer, based on the analysis of cell-free RNA in blood. By combining cutting-edge genomics with advanced...
Flomics Tackles Lung Cancer Relapse Detection with RNA-Based Liquid Biopsy in European Project LUMINA
Flomics participates in LUMINA, a Eurostars-funded project to detect lung cancer recurrence through liquid biopsy and artificial intelligence Barcelona – June 09, 2026 – Flomics Biotech is leading an international consortium that has been selected for...
BIOTEM project launch: Flomics expands to 7 Cancer types
Flomics will validate its cf-RNA liquid biopsy for 7 cancer types, adding liver and hematological tumors to its early detection pipeline. Flomics announces the launch of BIOTEM (“Biomarkers for Early Multicancer Detection”), a project to validate our...
Flomics contributes to the discovery of a circulating microRNA signature for PMM2-CDG diagnosis and monitoring
A new study led by researchers from Hospital Sant Joan de Déu (Barcelona) in collaboration with Flomics Biotech was published on October 13th in the Journal of Inherited Metabolic Disease. This study, titled “Exploring a circulating miRNA signature for PMM2-CDG:...
Closing meeting with the LiquiDx consortium
On 18th September 2025, the LiquiDx consortium gathered at the Biobanco del Sistema Sanitario Público de Andalucía (BBSSPA) facilities in Granada for the final face-to-face meeting of the project. The sessions, which were also transmitted by videoconference, served to...
Flomics Breakthrough in Liquid Biopsy: RNA & AI Enable Multicancer Early Detection
Flomics new study shows a cancer predictive power of 92% and high sensitivity in the early detection of five cancer types: colorectal, lung, breast, prostate and pancreas. Barcelona – January 31, 2025 – Flomics presented last week at the Liquid Biopsy...
Third face-to-face meeting of the LiquiDx project consortium
The LiquiDx consortium gathered for its third annual coordination meeting on 31st October 2024 at Leitat’s facilities at the Parc Cientific de Barcelona. The meeting reviewed the project’s progress toward developing a cutting-edge RNA-based blood diagnostic tool to...
First Freedom-to-operate study completed with the support of ACCIÓ
Flomics Biotech conducted an extensive Freedom-To-Operate (FTO) study in collaboration with ZBM Patents, an expert external IP firm. The study analysed 246 patent families related to cfRNA-based liquid biopsy technologies and confirmed that Flomics’ approach...
Successful Crowdfunding Campaign with Capital Cell
We have officially closed our crowdfunding campaign with Capital Cell! Running from June 18 to July 12, 2024, this campaign has been a testament to the strong belief and support we have toward our mission, proposal, and work. This milestone consolidates another step...